tetano
Editor, Senior Moderator
Diagn Microbiol Infect Dis
. 2020 Aug 11;98(4):115167.
doi: 10.1016/j.diagmicrobio.2020.115167. Online ahead of print.
Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test
Alexis C R Hoste[SUP] 1 [/SUP], Angel Venteo[SUP] 2 [/SUP], Alba Fresco-Taboada[SUP] 2 [/SUP], Istar Tapia[SUP] 2 [/SUP], Alejandro Monedero[SUP] 2 [/SUP], Lissette L?pez[SUP] 2 [/SUP], Maarten F Jebbink[SUP] 3 [/SUP], Elisa P?rez-Ram?rez[SUP] 4 [/SUP], Miguel Angel Jimenez-Clavero[SUP] 4 [/SUP], Mercedes Almonacid[SUP] 5 [/SUP], Patricia Mu?oz[SUP] 6 [/SUP], Jesus Guinea[SUP] 6 [/SUP], Carmen Vela[SUP] 2 [/SUP], Lia van der Hoek[SUP] 3 [/SUP], Paloma Rueda[SUP] 2 [/SUP], Patricia Sastre[SUP] 7 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)] to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2% and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered patients and identification of asymptomatic individuals.
Keywords: COVID-19; Diagnosis; ELISA; LFA; SARS-CoV-2; Serology.
. 2020 Aug 11;98(4):115167.
doi: 10.1016/j.diagmicrobio.2020.115167. Online ahead of print.
Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test
Alexis C R Hoste[SUP] 1 [/SUP], Angel Venteo[SUP] 2 [/SUP], Alba Fresco-Taboada[SUP] 2 [/SUP], Istar Tapia[SUP] 2 [/SUP], Alejandro Monedero[SUP] 2 [/SUP], Lissette L?pez[SUP] 2 [/SUP], Maarten F Jebbink[SUP] 3 [/SUP], Elisa P?rez-Ram?rez[SUP] 4 [/SUP], Miguel Angel Jimenez-Clavero[SUP] 4 [/SUP], Mercedes Almonacid[SUP] 5 [/SUP], Patricia Mu?oz[SUP] 6 [/SUP], Jesus Guinea[SUP] 6 [/SUP], Carmen Vela[SUP] 2 [/SUP], Lia van der Hoek[SUP] 3 [/SUP], Paloma Rueda[SUP] 2 [/SUP], Patricia Sastre[SUP] 7 [/SUP]
Affiliations
- PMID: 32890908
- DOI: 10.1016/j.diagmicrobio.2020.115167
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 8 million people worldwide, becoming a pandemic. Detecting antibodies against SARS-CoV-2 is of utmost importance and a good indicator of exposure and circulation of the virus within the general population. Two serological tools based on a double recognition assay [enzyme-linked immunosorbent assay (DR-ELISA) and lateral flow assay (DR-LFA)] to detect total antibodies to SARS-CoV-2 have been developed based on the recombinant nucleocapsid protein. A total of 1065 serum samples, including positive for COVID-19 and negative samples from healthy donors or infected with other respiratory pathogens, were analyzed. The results showed values of sensitivity between 91.2% and 100%, and specificity of 100% and 98.2% for DR-LFA and DR-ELISA, respectively. No cross-reactivity against seasonal coronavirus (HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43) was found. These results demonstrate the importance of serology as a complementary tool to polymerase chain reaction for follow-up of recovered patients and identification of asymptomatic individuals.
Keywords: COVID-19; Diagnosis; ELISA; LFA; SARS-CoV-2; Serology.